>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS

October 13 - 17 2012, 12:00 AM - 12:00 AM

ANESTHESIOLOGY 2012

>

FDA MEDWATCH ALERTS

RSS

May 16, 2012

Hydromorphone Hydrochloride Recall

Summary:

Hydromorphone Hydrochloride Recall

April 18, 2012

Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject by Hospira, Inc: Recall - May Contain More Than Intended Fill Volume

Summary:

Customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed. Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

March 05, 2012

Cardiac Science Powerheart, CardioVive, CardioLife; GE Responder and Responder Pro; and Nihon-Kohden Automated External Defibrillators (AEDs): Class I Recall - Defective Component

Summary: FDA notified healthcare professionals and medical care organizations of the Class 1 recall of the listed AEDs which contain a component that may fail unexpectedly due to a defect. If the component were to fail during a rescue attempt, the AED may not deliver defibrillation therapy, causing serious adverse health consequences, including death. The unit’s self test may not detect the failure or impending failure of the component.

>

ASA FEATURED PRODUCT

Anesthesiology Continuing Education (ACE) Program

SKU: 30702-12CE

... Read more »

Single Copies, Member Price: $300

The Wall Street Journal Reports Teva Will Stop Making Propofol

Teva Will Stop Making Anesthetic

Chicago — (March 30, 2010) 

Teva Pharmaceutical Industries Ltd. has told federal regulators that it will stop making the anesthetic propofol.

The injectable drug is one of the most widely used medicines for general anesthesia or sedation in operating rooms and intensive care units.

Doctors and the Food and Drug Administration have been concerned about a potential drug shortage since last fall.

Teva recalled some of the product in July 2009 after elevated levels of toxins were discovered at its Irvine, Calif., plant. The FDA said in a Dec. 11, 2009, warning letter released last month that it found "significant" manufacturing violations at the plant.

In a statement, the Israeli company said it is discontinuing its manufacture of propofol. "Our data supports that these products, when used and stored as directed, continue to be safe and effective and perform within the appropriate specification."

An FDA spokeswoman said propofol is still on its drug-shortage list. In November, the FDA took the unusual step of allowing APP Pharmaceuticals Inc., a subsidiary of Fresenius Kabi Pharmaceuticals Holding Inc., to import a similar product from one of its plants in Europe, after concerns about the shortage were raised by the American Society of Anesthesiologists.

The remaining U.S. propofol maker, Hospira Inc., has had two recalls, most recently on March 31. Hospira is not currently selling the product, a spokesman said. "We're implementing manufacturing changes to prevent the recurrence of a previous issue, and working with the FDA," he said.

THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS

Anesthesiologists: Physicians providing the lifeline of modern medicine. Founded in 1905, the American Society of Anesthesiologists is an educational, research and scientific association with 46,000 members organized to raise and maintain the standards of the medical practice of anesthesiology and improve the care of the patient.

For more information on the field of anesthesiology, visit the American Society of Anesthesiologists Web site at www.asahq.org. For patient information, visit LifeLineToModernMedicine.com

###

Contact:

American Society of Anesthesiologists
communications@asahq.org
847-825-5586